紧急管理和Medicaid注册的年轻儿童的喘风险,经常出现喘息
Isabel J Hardee1, Isabella Zaniletti2, Melisa S Tanverdi3
1Department of Pediatrics, University of CO School of Medicine, Children's Hospital Colorado, Aurora, CO, USA.
概括
患有反复喘息的幼儿,如果出现持续喘息,则有患儿喘的风险. 识别男性性别和黑人种族等风险因素可以帮助早期发现和预防喘.
科学领域:
- 儿科 儿科 儿科
- 呼吸系统医学 呼吸系统医学
- 流行病学 流行病学
背景情况:
- 幼儿的反复喘息是急诊室 (ED) 访问的常见原因.
- 识别患有持续喘息和随后儿童喘风险的儿童对于及时干预至关重要.
研究的目的:
- 描述幼儿的临床特征向ED提出早期复发性喘息.
- 确定与随后的持续喘息和儿童早期喘风险相关的因素.
主要方法:
- 一项回顾性队列研究分析了0-3岁的医疗补助计划儿童,他们有复发性喘息史.
- 从指数ED访问和随后的结果收集到4-6岁的数据.
- 后勤回归确定了持续喘息的风险因素.
主要成果:
- 包括超过41,000名儿童;28%的儿童在4-6岁之间经历了持续的喘息.
- 与持续喘息相关的因素包括男性性别,黑人种族,阿托皮和以前使用支气管扩展剂或皮质类固醇.
- 更多的喘息发作与ED喘药物治疗的几率增加有关.
结论:
- 患有持续喘息的幼儿面临患儿喘的风险增加.
- 在这个人群中早期识别持续喘息的危险因素可以促进早期的喘诊断和预防策略.
相关概念视频
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma-IV: Nursing Management
3.1K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
3.1K
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
Asthma: Pathogenesis and Management
403
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
403
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
298
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
298


